FrancophonIA/ELRC3.0 huggingface dataset:
English: Gently squeeze one drop of the medicine onto your eye. Make sure that the tip of the single-dose container does not touch your eye
Slovenian: Nežno vkapajte eno kapljico zdravila v oko.
English: Verkazia contains cetalkonium chloride
Slovenian: Zdravilo Verkazia vsebuje cetalkonijev klorid Cetalkonijev klorid lahko draži oči.
English: There was a significantly higher number of CFS responders in both active groups as compared to vehicle (p=0.005 for the high dose group, and p=0.010 for the low dose group) with 55.4%, 50.0% and 27.6% of responders in the high dose, low dose and vehicle groups respectively.
Slovenian: (p = 0,005 v skupini z velikim odmerkom in p = 0,010 v skupini z majhnim odmerkom) s 55,4 %,
English: Always use this medicine exactly as your doctor or pharmacist has told you.
Slovenian: Kako uporabljati zdravilo Verkazia Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika ali farmacevta.
English: Package leaflet: Information for the patient Verkazia 1 mg/mL eye drops emulsion ciclosporin
Slovenian: Navodilo za uporabo Verkazia 1 mg/ml kapljice za oko, emulzija ciklosporin (ciclosporin)
English: Therefore, caution should be exercised when corticosteroids are administered concomitantly with Verkazia.
Slovenian: Zato je pri dajanju kortikosteroidov skupaj z zdravilom Verkazia potrebna previdnost (glejte poglavje 4.5).
English: Children and adolescents
Slovenian: Odrasli
English: Gently shake the single-dose container
Slovenian: Enoodmerni vsebnik nežno premešajte.
English: Nervous system disorders
Slovenian: Bolezni živčevja pogosti glavobol
English: Inactivated bluetongue virus, serotype 8 (BTV-8), strain BEL2006/01 RP* ≥ 1 *Relative potency measured by ELISA in relation to a reference vaccine whose efficacy has been demonstrated by challenge in the target species.
Slovenian: --1 Inaktivirani virus bolezni modrikastega jezika, serotip 1 (BTV-1), sev ALG2006/01 E1 RP * ≥ 1 Inaktivirani virus bolezni modrikastega jezika, serotip 4 (BTV-4), sev BTV-4/SPA-1/2004 RP * ≥ 1 Inaktivirani virus bolezni modrikastega jezika, serotip 8 (BTV-8), sev BEL2006/01 RP * ≥ 1 * Relativna jakost, izmerjena s testom ELISA v zvezi z referenčnim cepivom, katerega učinkovitost je bila dokazana z izzivom pri ciljnih živalskih vrstah.
English: The Reference Member State was Netherlands and the Concerned Member States were Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain and Sweden.
Slovenian: Referenčna država članica je bila Nizozemska, zadevne države članice pa so bile Avstrija, Belgija, Ciper, Češka, Danska, Estonija, Finska, Francija, Nemčija, Grčija, Madžarska, Irska, Italija, Latvija, Litva, Luksemburg, Malta, Norveška, Poljska, Portugalska, Slovaška, Slovenija, Španija in Švedska.
English: London, 17 June 2008 EMEA/CHMP/332403/2008
Slovenian: London, 17. junija 2008 EMEA/340394/2008
English: During their December 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Yasminelle and associated names, that the objections raised by Hungary should not prevent the approval of the variation applied for and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be the final versions achieved during the Coordination group procedure.
Slovenian: Med svojim zasedanjem decembra 2007 je CHMP na podlagi vseh posredovanih podatkov in znanstvene razprave v okviru Odbora, sprejel mnenje, da je razmerje med koristmi in tveganji za zdravilo Belanette in z njim povezana imena ugodno, ter da ugovori, ki jih je podala Madžarska, ne bi smeli preprečiti odobritve vloge za spremembo in da naj bodo povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo referenčne države članice končne različice, dogovorjene med postopkom Skupine za usklajevanje.
English: Belanette and associated names, is a combined oral contraceptive containing 0.02 mg of ethinylestradiol and 3 mg of drospirenone.
Slovenian: Zdravilo Belanette in z njim povezana imena je kombinirano peroralno kontracepcijsko sredstvo, ki vsebuje 0,02 mg etinilestradiola in 3 mg drospirenona.
English: Belanette and associated names (see Annex I)
Slovenian: zdravilo Belanette in z njim povezana imena (glejte Dodatek I)
English: This summary was last updated in 08-2008.
Slovenian: Povzetek je bil nazadnje posodobljen 08-2008.
English: It is available as white tablets (round: 2.5, 5, 7.5 and 10 mg; oval: 15 and 20 mg).
Slovenian: Na voljo je v obliki belih tablet (okroglih: 2,5-, 5-, 7,5- in 10-miligramskih; ovalnih: 15- in 20-miligramskih).
English: It is known as an ‘atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s.
Slovenian: Spada med „atipične“ antipsihotike, ker se razlikuje od starejših antipsihotikov, ki so na voljo že od petdesetih let dvajsetega stoletja.
English: Olanzapine Mylan is not recommended for use in patients below 18 years of age because of a lack on information on safety and effectiveness in this age group.
Slovenian: Uporaba zdravila Olanzapine Mylan pri otrocih, mlajših od 18 let, zaradi pomanjkanja informacij o varnosti in učinkovitosti v tej starostni skupini ni priporočljiva.
English: Its exact mechanism of action is unknown, but it attaches to several receptors on the surface of nerve cells in the brain.
Slovenian: Natančen mehanizem delovanja zdravila ni znan, vendar pa se zdravilo veže z več receptorji na površini živčnih celic v možganih.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Olanzapine Mylan to Generics [UK] Ltd. on 7 October 2008.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Olanzapine Mylan, veljavno po vsej Evropski uniji, odobrila družbi Generics [UK] Ltd. dne 7. oktobra 2008.
English: The recommended starting dose of Olanzapine Mylan tablets depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day.
Slovenian: Priporočeni začetni odmerek zdravila Olanzapine Mylan je odvisen od bolezni, ki jo zdravimo: odmerek 10 mg na dan se uporablja pri shizofreniji in za preprečevanje maničnih epizod, odmerek 15 mg na dan pa se uporablja pri zdravljenju maničnih epizod, razen ob souporabi drugih zdravil, ko lahko začetni odmerek znaša 10 mg na dan.
English: It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine.
Slovenian: Domnevajo, da so koristni učinki olanzapina posledica blokiranja receptorjev za živčna prenašalca 5-hidroksitriptamin (imenovanim tudi serotonin) in dopamin.
English: It can also be used to prevent the recurrence (when symptoms come back) of these episodes in adults with bipolar disorder (a mental illness with alternating periods of high mood and depression) who have responded to an initial course of treatment.
Slovenian: Zdravilo se lahko uporablja tudi za preprečevanje ponovnega pojava simptomov teh epizod pri odraslih z bipolarno motnjo (duševno boleznijo, pri kateri se izmenjujejo obdobja privzdignjenega razpoloženja in depresije), ki so se odzvali na začetno zdravljenje.
English: Patients over 65 years of age and patients who have problems with their liver or kidneys may need a lower starting dose of 5 mg per day.
Slovenian: Razpon odmerkov je običajno od 5 do 20 mg na dan. Bolniki, starejši od 65 let, in bolniki, ki imajo težave z jetri ali ledvicami, bodo morda potrebovali nižji začetni odmerek, 5 mg na dan.
English: This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
Slovenian: S tem se prekinejo signali, ki potujejo med možganskimi celicami s pomočjo „živčnih prenašalcev“, kemičnih spojin, ki jih živčne celice uporabljajo za medsebojno sporočanje.
English: Olanzapine Mylan is also effective in maintaining improvement in patients who have responded to an initial course of treatment.
Slovenian: Zdravilo Olanzapine Mylan je prav tako učinkovito pri vzdrževanju izboljšanja stanja pri bolnikih, ki so se odzvali na začetno zdravljenje.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) OLANZAPINE MYLAN EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) OLANZAPINE MYLAN Povzetek EPAR za javnost
English: This means that Olanzapine Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zyprexa.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Zyprexa.
English: For more information on generic medicines, see the question-and-answer document here.
Slovenian: http://www.emea.europa.eu/Patients/generic.htmZa več informacij o generičnih zdravilih si oglejte dokument z vprašanji in odgovori, ki je na voljo tukaj.
English: Other information about Olanzapine Mylan:
Slovenian: Druge informacije o zdravilu Olanzapine Mylan:
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Olanzapine Mylan has been shown to have comparable quality and to be bioequivalent to Zyprexa.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v s skladu z zahtevami EU dokazano, da ima zdravilo Olanzapine Mylan primerljivo raven kakovosti kot zdravilo Zyprexa ter je biološko enakovredno.
English: Olanzapine Mylan is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Slovenian: Zdravilo Olanzapine Mylan se uporablja tudi za zdravljenje zmernih do težkih maničnih epizod (izjemno privzdignjeno razpoloženje) pri odraslih.
English: Because Olanzapine Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Slovenian: Ker je Olanzapine Mylan generično zdravilo in je biološko enakovreden referenčnemu zdravilu, ima enake koristi in tveganja kot referenčno zdravilo.
English: Because Olanzapine Mylan is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicine (i.e. that the two medicines produce the same levels of the active substance in the body).
Slovenian: Ker je zdravilo Olanzapine Mylan generično zdravilo, so bile študije omejene na teste, s katerimi se lahko dokaže, da je biološko enakovredno referenčnima zdraviloma (tj. da zdravili dosegata enake ravni zdravilne učinkovine v telesu).
English: Olanzapine Mylan is a ‘generic medicine'.
Slovenian: Olanzapine Mylan je „generično zdravilo“.
English: The Committee recommended that Olanzapine Mylan be given marketing authorisation.
Slovenian: Odbor je zato priporočil, da se za zdravilo Olanzapine Mylan odobri dovoljenje za promet.
English: Therefore, the CHMP's view was that, as for Zyprexa, the benefit outweighs the identified risk.
Slovenian: Zato je CHMP menil, da so koristi zdravila Olanzapine Mylan, tako kot pri zdravilu Zyprexa, večje od z njim povezanih tveganj.
English: What is the risk associated with Olanzapine Mylan?
Slovenian: Kakšna tveganja so povezana z zdravilom Olanzapine Mylan?
English: Olanzapine Mylan is a medicine containing the active substance olanzapine.
Slovenian: Olanzapine Mylan je zdravilo, ki vsebuje zdravilno učinkovino olanzapin.
English: Why has Olanzapine Mylan been approved?
Slovenian: Zakaj je bilo zdravilo Olanzapine Mylan odobreno?
English: The active substance in Olanzapine Mylan, olanzapine, is an antipsychotic medicine.
Slovenian: Zdravilna učinkovina zdravila Olanzapine Mylan je olanzapin, ki je antipsihotično zdravilo.
English: Olanzapine Mylan is used to treat adults with schizophrenia.
Slovenian: Zdravilo Olanzapine Mylan se uporablja za zdravljenje shizofrenije.
English: How has Olanzapine Mylan been studied?
Slovenian: Kako je bilo zdravilo Olanzapine Mylan raziskano?
English: What is Olanzapine Mylan?
Slovenian: Kaj je zdravilo Olanzapine Mylan?
English: What is Olanzapine Mylan used for?
Slovenian: Za kaj se zdravilo Olanzapine Mylan uporablja?
English: How is Olanzapine Mylan used?
Slovenian: Kako se zdravilo Olanzapine Mylan uporablja?
English: How does Olanzapine Mylan work?
Slovenian: Kako zdravilo Olanzapine Mylan deluje?
English: The full EPAR for Olanzapine Mylan can be found here.
Slovenian: http://www.emea.europa.eu/humandocs/Humans/EPAR/olanzapinemylan/olanzapinemylan.htmCelotn o Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Olanzapine Mylan je na voljo tukaj.
English: The recommended starting dose of Paglitaz is 15 or 30 mg once a day.
Slovenian: Priporočeni začetni odmerek zdravila Paglitaz je 15 ali 30 mg enkrat dnevno.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Paglitaz on 21 March 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Paglitaz, veljavno po vsej Evropski uniji, odobrila dne 21. marca 2012.
English: The full EPAR for Paglitaz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Paglitaz je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This means that Paglitaz is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
English: What are the benefits and risks of Paglitaz?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Paglitaz?
English: Treatment with Paglitaz should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Slovenian: Zdravljenje z zdravilom Paglitaz je treba po treh do šestih mesecih proučiti in prekiniti pri bolnikih, pri katerih ni zadostne koristi.
English: For more information about treatment with Paglitaz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Paglitaz preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: This is a summary of the European public assessment report (EPAR) for Paglitaz.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Paglitaz.
English: The active substance in Paglitaz, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Slovenian: Zdravilna učinkovina zdravila Paglitaz, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Paglitaz.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Paglitaz, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Paglitaz is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Slovenian: Zdravilo Paglitaz se uporablja za zdravljenje sladkorne bolezni tipa 2 pri odraslih (starejših od 18 let), zlasti tistih s prekomerno telesno maso.
English: Because Paglitaz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Paglitaz generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: Paglitaz is a medicine that contains the active substance pioglitazone.
Slovenian: Paglitaz je zdravilo, ki vsebuje zdravilno učinkovino pioglitazon.
English: Other information about Paglitaz
Slovenian: Druge informacije o zdravilu Paglitaz:
English: Because Paglitaz is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Slovenian: Ker je zdravilo Paglitaz generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
English: Paglitaz should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease).
Slovenian: Zdravilo Paglitaz se ne sme uporabljati pri bolnikih na dializi (tehniki čiščenja krvi, uporabljeni pri bolnikih z obolenjem ledvic).
English: The Committee recommended that Paglitaz be given marketing authorisation.
Slovenian: Odbor je zato priporočil, da se za zdravilo Paglitaz odobri dovoljenje za promet.
English: Paglitaz is a ‘generic medicine'.
Slovenian: Zdravilo Paglitaz je generično zdravilo.
English: Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk.
Slovenian: Zato je CHMP menil, da njegove koristi, tako kot pri referenčnem zdravilu Actos, odtehtajo znana tveganja.
English: Why has Paglitaz been approved?
Slovenian: Zakaj je bilo zdravilo Paglitaz odobreno?
English: The CHMP concluded that, in accordance with EU requirements, Paglitaz has been shown to have comparable quality and to be bioequivalent to Actos.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Paglitaz primerljivo raven kakovosti kot referenčno zdravilo Actos ter da mu je biološko enakovredno.
English: EPAR summary for the public pioglitazone
Slovenian: Povzetek EPAR za javnost
English: Paglitaz is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Slovenian: Zdravilo Paglitaz se uporablja samostojno pri bolnikih, za katere metformin (drugo zdravilo proti sladkorni bolezni) ni primerno.
English: Paglitaz can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Slovenian: Zdravilo Paglitaz se lahko uporablja tudi skupaj z insulinom pri bolnikih, pri katerih bolezen ni zadostno nadzorovana z insulinom samim in za katere metformin ni primeren.
English: Paglitaz can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy').
Slovenian: Zdravilo Paglitaz se lahko uporablja tudi v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče doseči zadovoljivega nadzora, ali v kombinaciji s sulfonilsečnino (drugo vrsto zdravila proti sladkorni bolezni), če metformin ni primeren (dvojno zdravljenje).
English: Paglitaz can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy').
Slovenian: Zdravilo Paglitaz se lahko uporablja tudi skupaj z metforminom in sulfonilsečnino hkrati pri bolnikih, pri katerih nadzor ni zadosten kljub dvojnemu peroralnemu zdravljenju (trojno zdravljenje).
English: What is Paglitaz?
Slovenian: Kaj je zdravilo Paglitaz?
English: What is Paglitaz used for?
Slovenian: Za kaj se zdravilo Paglitaz uporablja?
English: How has Paglitaz been studied?
Slovenian: Kako je bilo zdravilo Paglitaz raziskano?
English: How does Paglitaz work?
Slovenian: Kako zdravilo Paglitaz deluje?
English: How is Paglitaz used?
Slovenian: Kako se zdravilo Paglitaz uporablja?
English: A course of treatment usually lasts for 8 weeks.
Slovenian: Postopek zdravljenja traja običajno 8 tednov.
English: Date of renewal: 14 April 2004
Slovenian: Datum podaljšanja: 14. april 2004
English: This is extremely important because using more than one medicine at the same time may strengthen or weaken the effect of the medicines you are taking.
Slovenian: To je izjemno pomembno, kajti uporaba več kot enega zdravila sočasno lahko okrepi ali oslabi njegov učinek.
English: It may be given via a peripheral or central vein.
Slovenian: Lahko ga apliciramo v periferno ali centralno veno.
English: This first three months, is the most critical period post-transplantation.
Slovenian: Prvi trije meseci so najbolj kritično obdobje po presaditvi.
English: ● OTHER CONDITIONS
Slovenian: • DRUGI POGOJI
English: This is attributable to the humanisation of the protein.
Slovenian: To pripisujejo humanizaciji proteina.
English: In the event that you do develop an allergic reaction, your doctor will treat you with appropriate medication.
Slovenian: Če pri vas nastopi alergijska reakcija, vas bo zdravnik zdravil z ustreznimi zdravili.
English: Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http://www.emea.eu.int/
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http://www.emea.eu.int/.
English: If not used immediately, in use storage times and conditions prior to use are the responsibility of the user.
Slovenian: Če zdravilo ni porabljeno takoj, so čas shranjevanja in pogoji uporabe odgovornost uporabnika.
English: Medications for the treatment of severe hypersensitivity reactions should therefore be available for immediate use.
Slovenian: Zdravila za zdravljenje resnih preobčutljivostnih reakcij morajo biti na razpolago za takojšnjo uporabo.
English: The clinical relevance is unknown.
Slovenian: Klinični pomen teh ugotovitev ni poznan.
English: Pack sizes of 1 or 3.
Slovenian: Pakiranja po 1 ali 3.
English: It is not known if Zenapax is excreted in human milk.
Slovenian: Ni znano, ali se zdravilo Zenapax izloča v humano mleko.
English: From a microbiological point of view, however, the diluted product should be used immediately.
Slovenian: Vendar mora biti z mikrobiološkega stališča razredčena raztopina takoj uporabljena.
English: Once the infusion is prepared it should be administered intravenously immediately.
Slovenian: Ko je infuzija pripravljena, jo je potrebno takoj intravensko aplicirati.
English: Most of these high values occurred either on the first day post-transplant when patients received high doses of corticosteroids or in patients with diabetes.
Slovenian: Večina teh visokih vrednosti se je pojavila ali prvi dan po transplantaciji, ko so bolniki prejeli visoke odmerke kortikosteroidov ali pri sladkornih bolnikih.
English: The product is not intended to be stored after dilution unless the dilution has taken place under controlled and validated aseptic conditions.
Slovenian: Zdravilo ni namenjeno shranjevanju po razredčitvi, razen če je razredčitev potekala pod nadzorovanimi in validiranimi aseptičnimi pogoji.
English: You should not use this medicine if you are pregnant unless your doctor decides that it is necessary for you.
Slovenian: Tega zdravila med nosečnostjo ne smete uporabljati, razen če se zdravnik odloči, da je to za vas potrebno.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 26 February 1999
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 26. februar 1999
English: Instructions for the preparation of Zenapax infusions are described in section 6.6.
Slovenian: Navodila za pripravo infuzije zdravila Zenapax so opisana v poglavju 6.6.
English: Monoclonal antibodies are proteins which recognise and bind to other unique proteins in the body called antigens.
Slovenian: Monoklonska protitelesa so beljakovine, ki prepoznajo in se vežejo na druge posebne beljakovine v telesu, imenovane antigeni.